Maggiolo F - Search Results

1

Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group. Svicher V, et al. Among authors: maggiolo f. New Microbiol. 2012 Jan;35(1):17-25. Epub 2012 Jan 10. New Microbiol. 2012. PMID: 22378549 Free article.

2

Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.

Clerici M, Seminari E, Suter F, Castelli F, Pan A, Biasin M, Colombo F, Trabattoni D, Maggiolo F, Carosi G, Maserati R. Clerici M, et al. Among authors: maggiolo f. AIDS. 2000 Jan 28;14(2):109-16. doi: 10.1097/00002030-200001280-00005. AIDS. 2000. PMID: 10708280

3

Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.

Paolucci S, Baldanti F, Maserati R, Castelli F, Suter F, Maggiolo F, Pan A, Gerna G. Paolucci S, et al. Among authors: maggiolo f. Antiviral Res. 2000 Feb;45(2):101-14. doi: 10.1016/s0166-3542(00)00062-0. Antiviral Res. 2000. PMID: 10809019

4

Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients.

Baldanti F, Paolucci S, Maserati R, Maggiolo F, Pan A, Castelli F, Gulminetti R, Comolli G, Chiesa A, Gerna G. Baldanti F, et al. Among authors: maggiolo f. Eur J Clin Microbiol Infect Dis. 2000 May;19(5):380-4. doi: 10.1007/s100960050499. Eur J Clin Microbiol Infect Dis. 2000. PMID: 10898142

5

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.

Seminari E, Maggiolo F, Villani P, Suter F, Pan A, Regazzi MB, Paolucci S, Baldanti F, Tinelli C, Maserati R. Seminari E, et al. Among authors: maggiolo f. J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):453-60. doi: 10.1097/00126334-199912150-00005. J Acquir Immune Defic Syndr. 1999. PMID: 10961606 Clinical Trial.

6

Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART.

Baldanti F, Paolucci S, Gulminetti R, Maserati R, Migliorino G, Pan A, Maggiolo F, Comolli G, Chiesa A, Gerna G. Baldanti F, et al. Among authors: maggiolo f. Antiviral Res. 2001 Jun;50(3):197-206. doi: 10.1016/s0166-3542(01)00142-5. Antiviral Res. 2001. PMID: 11397507

7

Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.

Carosi G, Castelli F, Suter F, Maggiolo F, Orani AM, Pan A, Andreoni M, Vigevani GM, Maserati R, Mazzotta F, Tinelli C; MATER Study Group. Carosi G, et al. Among authors: maggiolo f. HIV Clin Trials. 2001 Sep-Oct;2(5):399-407. doi: 10.1310/5xcl-5xe9-jafk-xk7y. HIV Clin Trials. 2001. PMID: 11673814 Clinical Trial.

8

Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients.

Clerici M, Seminari E, Maggiolo F, Pan A, Migliorino M, Trabattoni D, Castelli F, Suter F, Fusi ML, Minoli L, Carosi G, Maserati R; Master Group. Clerici M, et al. Among authors: maggiolo f. AIDS. 2002 Sep 6;16(13):1767-73. doi: 10.1097/00002030-200209060-00009. AIDS. 2002. PMID: 12218388

9

Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.

Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'Aquila R, Lisziewicz J, Lori F. Foli A, et al. Among authors: maggiolo f. Antivir Ther. 2004 Feb;9(1):123-32. Antivir Ther. 2004. PMID: 15040544 Clinical Trial.

10

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F, Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V. Carosi G, et al. Among authors: maggiolo f. J Antimicrob Chemother. 2006 Jun;57(6):1055-64. doi: 10.1093/jac/dkl113. Epub 2006 Apr 10. J Antimicrob Chemother. 2006. PMID: 16606637

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters